ES2266093T3 - Utilizacion de peptidos y/o proteinas para la preparacion de un medicamento terapeutico y/o preventivo. - Google Patents

Utilizacion de peptidos y/o proteinas para la preparacion de un medicamento terapeutico y/o preventivo. Download PDF

Info

Publication number
ES2266093T3
ES2266093T3 ES01270546T ES01270546T ES2266093T3 ES 2266093 T3 ES2266093 T3 ES 2266093T3 ES 01270546 T ES01270546 T ES 01270546T ES 01270546 T ES01270546 T ES 01270546T ES 2266093 T3 ES2266093 T3 ES 2266093T3
Authority
ES
Spain
Prior art keywords
residue
ndsk
beta
mug
baselineskip
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES01270546T
Other languages
English (en)
Spanish (es)
Inventor
Peter Petzelbauer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fibrex Medical Research and Development GmbH
Original Assignee
Fibrex Medical Research and Development GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fibrex Medical Research and Development GmbH filed Critical Fibrex Medical Research and Development GmbH
Application granted granted Critical
Publication of ES2266093T3 publication Critical patent/ES2266093T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/363—Fibrinogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/75—Fibrinogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/0806—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
    • C07K5/1008—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Toxicology (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Transplantation (AREA)
  • Communicable Diseases (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Materials For Medical Uses (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
ES01270546T 2000-12-12 2001-12-07 Utilizacion de peptidos y/o proteinas para la preparacion de un medicamento terapeutico y/o preventivo. Expired - Lifetime ES2266093T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AT20632000 2000-12-12
ATA2063/2000 2000-12-12

Publications (1)

Publication Number Publication Date
ES2266093T3 true ES2266093T3 (es) 2007-03-01

Family

ID=3689750

Family Applications (2)

Application Number Title Priority Date Filing Date
ES01270546T Expired - Lifetime ES2266093T3 (es) 2000-12-12 2001-12-07 Utilizacion de peptidos y/o proteinas para la preparacion de un medicamento terapeutico y/o preventivo.
ES05012488T Expired - Lifetime ES2323963T3 (es) 2000-12-12 2001-12-07 Peptido y/o proteinas y su uso para la fabricacion de un medicamento terapeutico y/o preventivo.

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES05012488T Expired - Lifetime ES2323963T3 (es) 2000-12-12 2001-12-07 Peptido y/o proteinas y su uso para la fabricacion de un medicamento terapeutico y/o preventivo.

Country Status (30)

Country Link
US (4) US7271144B2 (https=)
EP (2) EP1586586B1 (https=)
JP (1) JP4181874B2 (https=)
KR (1) KR100864069B1 (https=)
CN (2) CN1518558B (https=)
AT (2) ATE329614T1 (https=)
AU (1) AU2002221316A1 (https=)
BG (1) BG107891A (https=)
BR (1) BR0116122A (https=)
CA (1) CA2430972C (https=)
CY (2) CY1106108T1 (https=)
CZ (1) CZ20031630A3 (https=)
DE (2) DE50110182D1 (https=)
DK (2) DK1341819T3 (https=)
EA (1) EA005576B1 (https=)
EE (1) EE200300283A (https=)
ES (2) ES2266093T3 (https=)
HR (1) HRP20030564A2 (https=)
HU (1) HUP0401536A3 (https=)
IL (2) IL156360A0 (https=)
MX (1) MXPA03005218A (https=)
NO (1) NO330767B1 (https=)
NZ (1) NZ550619A (https=)
PL (2) PL209752B1 (https=)
PT (2) PT1341819E (https=)
SI (2) SI1586586T1 (https=)
SK (1) SK7062003A3 (https=)
WO (1) WO2002048180A2 (https=)
YU (1) YU53803A (https=)
ZA (1) ZA200304545B (https=)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002221316A1 (en) 2000-12-12 2002-06-24 Fibrex Medical Research & Development Gmbh Peptides and/or proteins and use thereof for the production of a therapeutic and/or prophylactic medicament
CA2544676A1 (en) * 2004-06-25 2006-01-05 Fibrex Medical Research & Development Gesmbh Use of peptides derived from the a alpha or b beta chain of human fibrinogen for the treatment of shock
FR2879604B1 (fr) * 2004-12-22 2010-08-13 Biomerieux Sa Peptides citrullines derives de la fibrine reconnus par des auto-anticorps specifiques de la polyarthrite rhumatoide, et leurs utilisations
AT502987A1 (de) 2005-12-23 2007-07-15 Fibrex Medical Res & Dev Gmbh Pharmazeutische zusammensetzung zur behandlung von hämorrhagischem schock und seinen folgeerscheinungen
US20080004220A1 (en) * 2006-02-23 2008-01-03 Fibrex Medical Research & Development Gmbh Peptides and peptide derivatives, the production thereof as well as their use for preparing a therapeutically and/or preventively active pharmaceutical composition
WO2007095659A1 (de) * 2006-02-23 2007-08-30 Fibrex Medical Research & Development Gmbh Peptide und peptid-derivate, herstellun derselben sowie deren verwendung zur herstellung eines therapeutisch und/oder präventiv wirkenden arzneimittels
EP1987062B1 (en) * 2006-02-23 2011-06-22 Fibrex Medical Research & Development GmbH Peptides and peptide derivatives as well as pharmaceutical compositions containing the same
FR2900657B1 (fr) 2006-05-03 2009-04-17 Univ Toulouse Identification de modulateurs de l'activation des macrophages, utilisables pour le traitement de la polyarthrite rhumatoide
US8722623B2 (en) 2007-09-17 2014-05-13 University Of Maryland, Baltimore Compositions and methods utilizing fibrin beta chain fragments
FR2908134B1 (fr) * 2007-12-04 2012-10-12 Univ Toulouse 3 Paul Sabatier Identification de modulateurs de l'activation des macrophages, utilisables pour le traitement de la polyarthrite rhumatoide
WO2009096502A1 (ja) * 2008-01-31 2009-08-06 Japan As Represented By President Of National Center Of Neurology And Psychiatry うつ病およびうつ状態のマーカーおよびそれを用いた検出・診断
US20090286725A1 (en) * 2008-05-15 2009-11-19 Fibrex Medical Research & Development Gmbh Peptides and derivatives thereof, the manufacturing thereof as well as their use for preparing a therapeutically and/or preventively active pharmaceutical composition
US8088890B2 (en) * 2008-09-26 2012-01-03 Fibrex Medical Research & Development Gmbh Peptides and peptidomimetic compounds, the manufacturing thereof as well as their use for preparing a therapeutically and/or preventively active pharmaceutical composition
WO2010043444A2 (en) * 2008-10-15 2010-04-22 Fibrex Medical Research & Development Gmbh Pharmaceutical preparation for the treatment and/or prevention of ischemia/reperfusion injury and the sequels thereof
US20100152832A1 (en) * 2008-12-12 2010-06-17 Medtronic Vascular, Inc. Apparatus and Methods for Treatment of Aneurysms With Fibrin Derived Peptide B-Beta
US10531655B2 (en) 2011-12-02 2020-01-14 The Regents Of The University Of California Reperfusion protection solution and uses thereof
WO2017210539A1 (en) 2016-06-02 2017-12-07 University Of Maryland, Baltimore Compositions for inhibiting fibrin-vldl receptor-dependent inflammation and methods of treatment
EP3912679A1 (en) * 2020-05-19 2021-11-24 Johann Wolfgang Goethe-Universität Frankfurt am Main Bbeta-15-42 for the treatment of viral endothelitis

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4927916A (en) * 1984-04-23 1990-05-22 The General Hospital Corporation Method of producing fibrin-specific monoclonal antibodies lacking fibrinogen-cross-reactivity using fibrin-specific peptides
US5965107A (en) * 1992-03-13 1999-10-12 Diatide, Inc. Technetium-99m labeled peptides for imaging
DE19729591A1 (de) * 1997-07-10 1999-02-11 Therasorb Medizinische Systeme Mittel zur Behandlung und/oder Prophylaxe von Mikrozirkulationsstörungen
FR2795735B1 (fr) * 1999-07-01 2001-09-07 Univ Toulouse Derives citrullines de la fibrine et leur utilisation pour le diagnostic ou le traitement de la polyarthrite rhumatoide
AU2002221316A1 (en) * 2000-12-12 2002-06-24 Fibrex Medical Research & Development Gmbh Peptides and/or proteins and use thereof for the production of a therapeutic and/or prophylactic medicament
US7201763B2 (en) 2001-10-24 2007-04-10 Boston Scientific Scimed, Inc. Distal balloon waist material relief and method of manufacture

Also Published As

Publication number Publication date
HUP0401536A2 (hu) 2004-11-29
CY1106108T1 (el) 2011-06-08
SI1341819T1 (sl) 2006-10-31
BG107891A (bg) 2004-08-31
CY1109107T1 (el) 2014-07-02
NO330767B1 (no) 2011-07-11
CA2430972A1 (en) 2002-06-20
HRP20030564A2 (en) 2005-06-30
WO2002048180A3 (de) 2003-01-30
EE200300283A (et) 2003-10-15
EP1586586B1 (de) 2009-03-11
SK7062003A3 (en) 2003-11-04
US20040192596A1 (en) 2004-09-30
NZ550619A (en) 2008-06-30
IL156360A0 (en) 2004-01-04
US20090088384A1 (en) 2009-04-02
JP4181874B2 (ja) 2008-11-19
EA200300678A1 (ru) 2003-10-30
IL156360A (en) 2012-12-31
JP2004527469A (ja) 2004-09-09
EP1586586A2 (de) 2005-10-19
US20070037749A1 (en) 2007-02-15
US7811985B2 (en) 2010-10-12
ES2323963T3 (es) 2009-07-28
WO2002048180A2 (de) 2002-06-20
US7494973B2 (en) 2009-02-24
EA005576B1 (ru) 2005-04-28
PL209419B1 (pl) 2011-08-31
US20090137464A1 (en) 2009-05-28
YU53803A (sh) 2006-03-03
NO20032656D0 (no) 2003-06-12
DK1586586T3 (da) 2009-06-29
DE50114771D1 (de) 2009-04-23
PT1586586E (pt) 2010-05-28
US7271144B2 (en) 2007-09-18
KR20030060988A (ko) 2003-07-16
CZ20031630A3 (cs) 2003-10-15
PL362924A1 (en) 2004-11-02
EP1341819A2 (de) 2003-09-10
MXPA03005218A (es) 2004-12-03
PL209752B1 (pl) 2011-10-31
EP1341819B1 (de) 2006-06-14
ZA200304545B (en) 2004-09-13
NO20032656L (no) 2003-06-12
SI1586586T1 (sl) 2009-08-31
KR100864069B1 (ko) 2008-10-16
DK1341819T3 (da) 2006-10-16
ATE425184T1 (de) 2009-03-15
AU2002221316A1 (en) 2002-06-24
HK1084400A1 (zh) 2006-07-28
DE50110182D1 (de) 2006-07-27
BR0116122A (pt) 2003-10-14
PT1341819E (pt) 2006-10-31
HUP0401536A3 (en) 2008-09-29
CN1518558A (zh) 2004-08-04
CN101676299A (zh) 2010-03-24
CA2430972C (en) 2014-08-05
ATE329614T1 (de) 2006-07-15
CN1518558B (zh) 2010-06-16
EP1586586A3 (de) 2006-03-29
US8067373B2 (en) 2011-11-29

Similar Documents

Publication Publication Date Title
ES2266093T3 (es) Utilizacion de peptidos y/o proteinas para la preparacion de un medicamento terapeutico y/o preventivo.
US5100875A (en) Novel peptides having plateler aggregation inhibitory activity
ES2371038T3 (es) Péptidos y derivados peptídicos así como composiciones farmacéuticas que contienen los mismos.
ES2438779T3 (es) Péptidos administrados oralmente para mejorar aterosclerosis
JPH03118330A (ja) フイブリノーゲンレセプター拮抗剤
JP3711154B2 (ja) 一般式ｉのシクロペプチド
JPH03118331A (ja) 環状フイブリノーゲンレセプター拮抗薬
JP2004527469A6 (ja) ペプチドおよび／またはタンパク質、並びにその治療用および／または予防用医薬成分を調製するための使用
JP2011523634A (ja) ペプチド、ペプチド模倣物およびそれらの誘導体、それらの製造、ならびに治療および／または予防活性のある医薬組成物を調製するためのそれらの使用
KR100186656B1 (ko) 신규한 펩타이드, 및 전기 펩타이드를 이용하는 혈소판 응집저해제, 체외순환하는 혈액의 혈액응고 저해제, 세포점착저해제, 종양전이 저해제, 수혈용 혈소판 제제의 보호제, 수혈용 혈소판 제제 및 혈소판 제제 팩
ES2358018T3 (es) Uso de compuestos de kahalalida para la fabricación de un medicamento para el tratamiento de la psoriasis.
ES2217255T3 (es) Composiciones polipeptidicas farmaceuticas que contienen lisina y uso de las mismas.
AU690923B2 (en) Linear adhesion inhibitors
Zhao et al. Studies on hybrid peptides of fragments from fibrinogen
HK1140212A (en) Peptides and/or proteins and use thereof for the production of a therapeutic and/or prophylactic pharmaceutical
JPH083065A (ja) 肝臓障害に対する治療剤
HK1084400B (en) Peptide and/or proteins and their use for the manufacture of a therapeutic and/or preventive medicament
RU2002124494A (ru) Ингибиторы интегрина αvβ6
JPH06228189A (ja) ペプチド誘導体およびその用途